You are here
Shelf Life for Immune Globulin Intravenous (Human) Extended From 24 to 36 Months
Privigen is the first and only 10 percent liquid IVIg stabilized with proline, a naturally occurring amino-acid. The product is indicated for primary immunodeficiency (PI), a group of disorders, usually genetic, that result from a malfunction in part or all of the immune system. This condition prevents patients from fighting off infections caused by everyday germs. Privigen is also indicated for the treatment of patients with chronic immune thrombocytopenic purpura (ITP) to raise platelet counts.
Proline efficiently minimizes dimer formation (less than or equal to 12% dimers) and allows storage of Privigen at room temperature (up to 25 degrees C [77 degrees F]) throughout its entire 36-month shelf life. Because the product does not need refrigeration, Privigen is always ready for immediate use. As a liquid IVIg, it also requires no reconstitution, which saves preparation time and minimizes product waste.
"CSL Behring has a history of developing innovative immunoglobulin therapies and we continually strive to enhance the quality of the life-saving products our patients depend on," said Robert Lefebvre, Vice President and General Manager, U.S. Commercial Operations at CSL Behring. "Part of that commitment includes convenience for patients and health providers. The approval of an extended shelf life for Privigen is another example of our dedication to meeting customer needs."
The sBLA for Privigen was based on a three-year study assessing the product's stability. Physicochemical, biological and immunological parameters were assessed during 36 months' storage under controlled conditions at 25 degrees C (77 degrees F). Over the 36 months, the IgG fraction in Privigen maintained high purity (greater than or equal to 98%) and no relevant amounts of aggregated IgG molecules were formed. Also, the use of proline at pH 4.8 inhibited dimer formation (less than or equal to 12%) throughout the study period.
Privigen is part of the Ig franchise of CSL Behring. This comprehensive immunoglobulin product portfolio also includes the first 16 percent and first 20 percent subcutaneous immunoglobulin (SCIg) therapies approved in the U.S. by the FDA. CSL Behring manufactures Privigen at its state-of-the art facility in Bern, Switzerland where the most advanced technologies are applied to ensure product safety and ample supply. This facility represents the long-term commitment of CSL Behring to global Ig markets.
Source: CSL Behring